$8.69
5.98% today
Nasdaq, May 30, 07:31 pm CET
ISIN
US74584P1030
Symbol
PULM
Sector
Industry

Pulmatrix Inc Stock price

$8.20
+1.90 30.16% 1M
+1.56 23.49% 6M
+1.22 17.48% YTD
+6.32 336.82% 1Y
+3.02 58.30% 3Y
-25.40 75.60% 5Y
-1,976.80 99.59% 10Y
Nasdaq, Closing price Thu, May 29 2025
-0.89 9.79%
ISIN
US74584P1030
Symbol
PULM
Sector
Industry

Key metrics

Market capitalization $29.95m
Enterprise Value $22.24m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 11.58
P/S ratio (TTM) P/S ratio 15.60
P/B ratio (TTM) P/B ratio 4.19
Revenue growth (TTM) Revenue growth -83.56%
Revenue (TTM) Revenue $1.92m
EBIT (operating result TTM) EBIT $-12.36m
Free Cash Flow (TTM) Free Cash Flow $-10.05m
Cash position $7.71m
EPS (TTM) EPS $-3.34
Short interest 0.66%
Show more

Is Pulmatrix Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,782 stocks worldwide.

Pulmatrix Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Pulmatrix Inc:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Pulmatrix Inc:

Buy
100%

Financial data from Pulmatrix Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
1.92 1.92
84% 84%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 7.99 7.99
35% 35%
416%
- Research and Development Expense 3.67 3.67
76% 76%
191%
-12 -12
30% 30%
-624%
- Depreciation and Amortization 0.38 0.38
138% 138%
20%
EBIT (Operating Income) EBIT -12 -12
31% 31%
-644%
Net Profit -12 -12
38% 38%
-635%

In millions USD.

Don't miss a Thing! We will send you all news about Pulmatrix Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Pulmatrix Inc Stock News

Neutral
PRNewsWire
15 days ago
Registration statement for proposed Cullgen merger declared effective by the SEC Proposed merger anticipated to close in June As part of proposed merger, Pulmatrix currently intends to divest its assets including its Phase 2-ready acute migraine candidate, PUR3100, and other development candidates based on its iSPERSE™ technology FRAMINGHAM, Mass. , May 15, 2025 /PRNewswire/ -- Pulmatrix, Inc. ...
Neutral
Business Wire
21 days ago
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Pulmatrix, Inc. (NasdaqCM: PULM) and Cullgen Inc. Pursuant to the terms of the agreement, upon completion of the Merger, Pulmatrix stockholders are expected to own approximately 3.6% of the combined company. KSF...
Neutral
PRNewsWire
2 months ago
Announced merger agreement with Cullgen in November, anticipated to close in the first half of 2025 As part of proposed merger, Pulmatrix intends to divest its assets including its Phase 2-ready acute migraine candidate, PUR3100, and other development candidates based on its iSPERSE™ technology FRAMINGHAM, Mass. , March 21, 2025 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Na...

Company Profile

Pulmatrix, Inc. is a clinical stage biotechnology company, which engages in the discovery and development of novel inhaled therapeutic products for respiratory and other diseases. The firm focuses on the prevention and treatment of respiratory diseases and infections. It offers products based on its proprietary dry powder delivery technology, iSPERSE, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The company was founded by David Alan Edwards, Mark J. Gabrielson, Alexander M. Klibanov, and Robert S. Langer, Jr. on June 15, 2015 and is headquartered in Lexington, MA.

Head office United States
CEO Peter Ludlum
Employees 2
Founded 2015
Website www.pulmatrix.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today